A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Entospletinib (Primary) ; Tirabrutinib (Primary) ; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 10 Sep 2017 Planned number of patients changed from 60 to 36.
- 28 Aug 2017 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
- 17 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 1 May 2018.